MedTrace Logo

Reversibility of Dual Antiplatelet Therapy by Platelets

NCT01248351 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2011-04-28

No results posted yet for this study

Summary

The objective of the study is to test the hypothesis whether or not autologous stored platelets are able to offset the antiplatelet effect of aspirin and clopidogrel as assessed by state-of-the-art platelet function assays.

Conditions

Interventions

OTHER

autologous stored platelets

Administration of autologous stored platelets

OTHER

administration of autologous stored platelets

administration of autologous stored platelets

BIOLOGICAL

autologous stored platelets

transfusion of autologous stored platelets

Sponsors & Collaborators

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • CSL Behring

    collaborator INDUSTRY

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Mahla Elisabeth, MD · Dept. of Anesthesia and Intensive Care Medicine, Medical University of Graz

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-02-28
Completion
2011-03-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01248351 on ClinicalTrials.gov